Relapsed or Refractory T Cell Lymphoma
specificAn enteropathy-associated T-cell lymphoma that is resistant to treatment.
12
Centers
12
Active Trials
—
Cancer Funding
Top Centers for Relapsed or Refractory T Cell Lymphoma(12)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 54.2 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 54.2 |
| 3 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive Active Research Program | 54.2 |
| 4 | Yale Cancer Center Yale School of MedicineNew Haven, CT NCI Comprehensive Active Research Program | 54.2 |
| 5 | Vanderbilt-Ingram Cancer CenterNashville, TN NCI Comprehensive Active Research Program | 54.2 |
| 6 | Herbert Irving Comprehensive Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 54.2 |
| 7 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive Active Research Program | 54.2 |
| 8 | City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive Active Research Program | 54.2 |
| 9 | Roswell Park Comprehensive Cancer CenterBuffalo, NY NCI Comprehensive Active Research Program | 54.2 |
| 10 | Cleveland Clinic Cancer CenterCleveland, OH Active Research Program | 54.2 |
| 11 | Boston University Cancer CenterBoston, MA Active Research Program | 54.2 |
| 12 | Karmanos Cancer InstituteDetroit, MI NCI Comprehensive Active Research Program | 54.2 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →